$1.27 EPS Expected for Eiger BioPharmaceuticals, Inc. (EIGR) This Quarter

Author

17 July, 2017

Investors and Traders continue to monitor technical levels of shares of EigerBioPharmaceuticals, Inc. (NASDAQ:ALDR) from a strong sell rating to a sell rating in a report issued on Tuesday, June 20th. The consensus price target of $11.00 also implies significant upside from the current price of $3.25.

Eiger BioPharmaceuticals, Inc. (EIGR), a part of Healthcare sector and belongs to Biotechnology industry; ended its day with gain 24.16% and finalized at the price of $9.25. It discovers, develops and seeks to commercialize therapeutic antibodies. Alder Biopharmaceuticals Inc.is headquartered in Bothell, Washington.

Several other research analysts also recently commented on the company. Aegis restated a buy rating and issued a $41.00 price target on shares of Alder BioPharmaceuticals in a research note on Tuesday, April 25th.

Among 12 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 10 have Buy rating, 1 Sell and 1 Hold. Credit Suisse Group downgraded Alder BioPharmaceuticals from an "outperform" rating to a "neutral" rating and cut their target price for the stock from $30.00 to $17.00 in a report on Wednesday, June 28th. Needham & Company LLC started coverage on shares of Alder BioPharmaceuticals in a research note on Monday, May 15th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company.

Shares of Alder BioPharmaceuticals (NASDAQ:ALDR) traded up 3.00% on Tuesday, reaching $12.00. The firm's 50-day moving average is $17.14 and its 200 day moving average is $20.51. The stock's market cap is $77.39 million.

Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its earnings results on Thursday, April 27th. Analysts forecast earnings per share of $-1.71, down exactly $0.92 or 116.46 % from 2014's $-0.79 EPS. Eiger BioPharmaceuticals posted earnings of ($1.87) per share during the same quarter last year, which would indicate a positive year over year growth rate of 32.1%.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of United States & global copyright legislation. The legal version of this news story can be accessed at https://www.com-unik.info/2017/07/17/alder-biopharmaceuticals-inc-aldr-set-to-announce-quarterly-earnings-on-monday.html. The stock grabbed 19 new institutional investments totaling 868,765 shares while 14 institutional investors sold out their entire positions totaling 973,525 shares. Bank of New York Mellon Corp raised its stake in Eiger BioPharmaceuticals by 4.7% in the first quarter. Analysts expect the company to announce earnings of ($1.61) per share for the quarter. Cypress Capital Group sold 2,933 shares as Celgene Corp (CELG)'s stock declined 3.49%. Janus Capital Management LLC now owns 5,167,085 shares of the biopharmaceutical company's stock valued at $107,473,000 after buying an additional 230,044 shares during the period. Finally, Perceptive Advisors LLC purchased a new stake in Eiger BioPharmaceuticals during the fourth quarter valued at about $1,836,000. Goldman Sachs Group Inc. owned 1.33% of Alder BioPharmaceuticals worth $13,917,000 as of its most recent filing with the SEC. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.


More news